Search

Meet Antonio Almeida, our February Volunteer of the Month

EHA is a Public Benefit Organization under Dutch law.

Read more

Meet Fabienne Lucas, our January Volunteer of the Month

EHA is a Public Benefit Organization under Dutch law.

Read more

Meet Fabienne Lucas, our January Volunteer of the Month

EHA is a Public Benefit Organization under Dutch law.

Read more

International Survey of T2* Cardiovascular Magnetic Resonance in Thalassemia

Thalassemia major (TM) is a substantial health issue, with over 25,000 new transfusion- dependent children identified each year around the world.

Read more

Highlights of the EHA-EMA Joint Symposium on RWE

The fourth EHA-EMA Joint Symposium at EHA2024 brought together investigators, regulators and patients to discuss the use of real world evidence (RWE) in the evaluation of new drugs.

Read more

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Read more

EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders

EHA Hematology Tutorial in collaboration with the Indian Society of Hematology & Blood Transfusion

Dates: February 16-18, 2018
Location: Lucknow, India
Chairs: AK Tripathi & G Gaidano

Goal of the meeting
This three day event aims to increase the knowledge of participants on how to provide…

Read more

The EHA Guidelines Workshop, a meaningful and successful first Series!

November 2020 – April 2021

In the past six months, hematologists, clinicians, transfusion medicine specialists, oncologists, special nurses and researchers gathered virtually for the first EHA Guidelines Workshop series.

Read more

Dutch scientists propose algorithm to keep drugs affordable and accessible

May 8, 2018, The Hague - An important contribution to the debate about the affordability and accessibility of innovative medicines appeared in Nature Reviews, proposing the adoption of a novel model of price setting with examples of implementation.

Read more